EUVIMEDEUVIMED entdecken
Open Access

Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s disease

Jeha Jeon, Young Cha, Yean Ju Hong, In-Hee Lee, Heejin Jang, Sanghyeok Ko, Serhiy Naumenko, Minseon Kim, Hannah L Ryu, Zenith Shrestha, Nayeon Lee, Tae-Yoon Park und 10 weitere

Cell Stem Cell · 2025-03 · 32 (3) · 343-360.e7

DOI: 10.1016/j.stem.2025.01.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Stem Cell, 2025-03. Verfasst von Jeha Jeon und 21 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Neurobiology Laboratory, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA; Program in Neuroscie…. Hauptthemen laut MEDLINE: Parkinson Disease, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic cells (mDACs) represent a promising source for autologous cell therapy in Parkinson's disease (PD), but standardized regulatory criteria are essential for clinical translation. In this pre-clinical study, we generated multiple clinical-grade hiPSC lines from freshly biopsied fibroblasts of four sporadic PD patients using episomal reprogramming and differentiated them into mDACs using a refined 21-day protocol. Rigorous evaluations included whole-genome/exome sequencing, RNA sequencing, and in vivo studies, including a 39-week Good Laboratory Practice-compliant mouse safety study. While mDACs from all lines met safety criteria, mDACs from one patient failed to improve rodent behavioral outcomes, underscoring inter-individual variability. Importantly, in vitro assessments did not reliably predict in vivo efficacy, identifying dopaminergic fiber density as a key efficacy criterion. These findings support comprehensive quality control guidelines for autologous cell therapy and pave the way for a clinical trial with eight sporadic PD patients, scheduled to commence in 2025.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseInduced Pluripotent Stem CellsCell- and Tissue-Based TherapyHumansAnimalsDopaminergic NeuronsMiceTransplantation, AutologousMaleCell DifferentiationFemaleMiddle AgedAged

Stichwörter der Autor:innen

Parkinson's diseaseautologous cell therapydopaminergic fiber densitygenome integrityhuman induced pluripotent stem cellsinter-individual variabilitymidbrain dopaminergic cellsphase 1 clinical trialpre-clinical studysafety and efficacy

Autor:innen und Institutionen

  • Molecular Neurobiology Laboratory, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA; Program in Neuroscience, Harvard Medical School, Belmont, MA 02478, USA.
  • Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA 02215, USA.
  • Molecular Neurobiology Laboratory, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA; Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAI…
  • Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.
  • Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health
  • Massachusetts General Hospital
  • McLean Hospital

Zitieren

APA

Jeon, J., Cha, Y., Hong, Y. J., Lee, I. H., Jang, H., Ko, S., Naumenko, S., Kim, M., Ryu, H. L., Shrestha, Z., Lee, N., Park, T. Y., Park, H., Kim, S. H., Yoon, K. J., Song, B., Schweitzer, J., Herrington, T. M., Kong, S. W., …, & Kim, K. S. (2025). Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s disease. Cell Stem Cell, 32(3), 343-360.e7. https://doi.org/10.1016/j.stem.2025.01.006

Vancouver

Jeon J, Cha Y, Hong YJ, Lee IH, Jang H, Ko S, et al. Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s disease. Cell Stem Cell. 2025;32(3):343-360.e7. doi:10.1016/j.stem.2025.01.006

BibTeX
@article{Jeon2025,
  author = {Jeon, Jeha and Cha, Young and Hong, Yean Ju and Lee, In-Hee and Jang, Heejin and Ko, Sanghyeok and Naumenko, Serhiy and Kim, Minseon and Ryu, Hannah L and Shrestha, Zenith and Lee, Nayeon and Park, Tae-Yoon and Park, HoeWon and Kim, Seo-Hyun and Yoon, Ki-Jun and Song, Bin and Schweitzer, Jeffrey and Herrington, Todd M and Kong, Sek Won and Carter, Bob and Leblanc, Pierre and Kim, Kwang-Soo},
  title = {Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s disease},
  journal = {Cell Stem Cell},
  year = {2025},
  volume = {32},
  number = {3},
  pages = {343--360.e7},
  doi = {10.1016/j.stem.2025.01.006}
}
Kostenlos starten →